Pfizer Files Supplemental Proxy Materials

TL;DR

Pfizer sent an email to shareholders, filing supplemental proxy docs. No new fee.

AI Summary

Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 10, 2025, indicating it sent a form of email to certain shareholders. This filing is a supplement to their proxy statement and does not require a new filing fee, as a fee was either not required or paid previously.

Why It Matters

This filing provides an update to shareholders regarding communications and ensures compliance with SEC proxy solicitation rules.

Risk Assessment

Risk Level: low — This is a routine supplemental filing for a proxy statement, not indicating any new or unusual risks for the company.

Key Players & Entities

• Pfizer Inc. (company) — Registrant
• April 10, 2025 (date) — Filing date and email distribution date
• 66 HUDSON BOULEVARD EAST (address) — Pfizer's business and mailing address
• NEW YORK (location) — City for Pfizer's address
• 10001-2192 (zip_code) — Zip code for Pfizer's address

FAQ

From the Filing

0000078003-25-000092.txt : 20250410 0000078003-25-000092.hdr.sgml : 20250410 20250410082224 ACCESSION NUMBER: 0000078003-25-000092 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250410 DATE AS OF CHANGE: 20250410 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25826577 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 DEFA14A 1 supplementala041025.htm DEFA14A Supplemental A 04.10.25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Pfizer Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of filing fee (Check all boxes that apply): x No fee required ¨ Fee paid previously with preliminary materials ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 On April 10, 2025, the following form of email was sent to certain Pfizer Inc. shareholders: From: Investor Insights Subject: Save the date: Pfizer’s Virtual Annual Meeting on April 24th Headline: Participate in the Annual Meeting by exercising your right to vote! In 2024, Pfizer successfully executed a year of transformative change and advanced innovation, realigning the R&D organization to help drive progress, making a positive impact for patients and strengthening our position as we strive to deliver shareholder value. Reflecting on 2024 In 2024, Pfizer achieved significant milestones, including: • Reaching more than 414 million patients1 around the world with our medicines and vaccines, contributing to our goal of impacting one billion lives by 2027. • For the full year of 2024, we reported total revenues of $63.6 billion, reflecting 7% year-over- year operational growth. Our operational revenue growth when excluding contributions from our COVID-19 products was 12%.2 • We had a strong year of R&D pipeline performance in 2024. In addition to the 14 regulatory approvals we received from the U.S. Food and Drug Administration and the European Medicines Agency, we had 7 pivotal study starts and 8 key Phase 3 readouts. Our robust pipeline of potential new medicines and vaccines is at the very heart of our ability to change people’s lives. Upcoming Annual Meeting of Shareholders Pfizer’s upcoming 2025 Annual Meeting of Shareholders will take place virtually on April 24th at 9 a.m. EDT, providing an opportunity for all Pfizer shareholders to vote on the important matters at the meeting and hear from Pfizer leadership about our strategy, financial performance and more. Your vote is important. For information regarding how to vote your shares by telephone, by internet, by mail or at the virtual Annual meeting see “Annual Meeting Information – Voting” in Pfizer’s Proxy Statement. 1 The Patients Reached metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by external sources (e